Spotlight: EU backs label expansions for 3 companies' meds

Every drugmaker wants to find differentiators for their products. And for Ironwood ($IRWD), it was obvious. "Is this a constipation drug that improves abdominal symptoms, or is this an abdominal pain drug that improves constipation?" chief commercial officer Tom McCourt first asked company R&D chief Mark Currie. And because it was the latter, Ironwood and partner Allergan ($AGN) now stand apart from OTC offerings, a position that helped them grow U.S. sales to $454.8 million last year. More from FiercePharmaMarketing

@FiercePharma: Tokyo-listed SanBio gets Japan PMDA nod for brain trauma stem cell trial. Article | Follow @FiercePharma

@EricPFierce: Unable to find a buyer, Sun will close the Ranbaxy plant in Ireland, lay off 70 remaining workers. Story | Follow @EricPFierce

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

@CarlyHFierce: Facing a new assessment of Kyprolis, Amgen castigates cost-effectiveness team's methods. More | Follow @CarlyHFierce

> Japan-based Eisai has teamed up with PharmStandard to localize production in Russia, in hopes of broadening access to its drugs there. Report

> European regulators backed a label update for Medivation's ($MDVN) prostate cancer drug Xtandi. Report

> Boehringer Ingelheim's new lung cancer drug Giotrif won a new, targeted use in that disease in Europe. Report

> Novartis ($NVS) won EU approval for Revolade as a treatment for children with chronic idiopathic thrombocytopenic purpura (ITC); the approval covers tablets and a new oral suspension formula. Release

Medical Device News

@FierceMedDev: Illumina expands San Diego HQ with new Blackrock-owned digs starting mid-2017. Story | Follow @FierceMedDev

@EmilyWFierce: Gilead keeps Martin's pay going strong at $18.8M in his last year as CEO. More | Follow @EmilyWFierce

> FDA approves first leadless, transcatheter pacemaker for Medtronic, St. Jude up next. Story

> IBM and Pfizer join forces for real-time patient monitoring system for Parkinson's. More

Biotech News

@FierceBiotech: $BIND Therapeutics looks for immuno-oncology partner, CEO tells FierceBiotech he may have to sell the company. Story | Follow @FierceBiotech

@JohnCFierce: A capricious bureaucracy taking something away is irritating. Treasury targeting a megainversion is predictable. | Follow @JohnCFierce

> Heat Biologics to slash staff by a fifth, cut more than half of patients in cancer trial. Story

> Roche steps in to help fund $34M Lumos round for rare disease R&D. More

Pharma Asia News

> China biotech Essex Bio signs $3.5M antibodies deal with U.S. antibody specialist Abpro. Item

> Tokyo-listed SanBio gets Japan PMDA nod for brain trauma stem cell trial. Article

> Eisai to work with Russia's PharmStandard on oncology manufacture. News

> Lupin's new M&A deals to strike at Indian rival Sun's perch in Japan. More

> Drug price cuts in Japan sink in though details sparse. Story

CRO News

> Failure of Pfizer-Allergan deal may hit CROs long term. More

> QPS expands biologics service with SCIEX deal. Article

> InVentiv to go public, hopes to raise $500M. Story

> GE Healthcare rolls out new R&D partnership in Turkey. News

> SynteractHCR sends team to the American Lung Association's 'Fight for Air Climb.' More

Pharma Manufacturing News

> Pfizer recalls mislabeled bottles of adult Robitussin. More

> Eisai turns to PharmStandard for manufacturing in Russia. Article

> New player jumping into cell therapies manufacturing. Story

> Teva expands API site in Hungary. News

> Pfizer to look for 20% cost cuts in some manufacturing, Ireland employees told. Report

And Finally... U.S. lifespan is weighed down by obesity, JAMA says. Report

Suggested Articles

Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.

With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.